Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ten Carbon Chemistry is an Australian biotechnology company specializing in the development of high-performance, non-toxic antimicrobial solutions based on proprietary fatty acid technology. A spin-off of Wintermute Biomedical, the company's core platform, GS-2, utilizes a patented method to make capric acid (a ten-carbon fatty acid) water-soluble without the use of toxic solvents. This technology effectively disrupts the lipid membranes of bacteria, fungi, and enveloped viruses while maintaining a high safety profile for humans and the environment. TCC's products, including the Doxall range, are applied across healthcare, agriculture, food processing, and industrial sectors to combat antimicrobial resistance and enhance biosecurity. The company is actively expanding its portfolio into medical device coatings and advanced wound care applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ten Carbon Chemistry.